Trial
NCT03827473
Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Utah
Collaborators
—
Condition
Castration-Sensitive Prostate Carcinoma
Intervention
Abiraterone Acetate
Why stopped
The trial was closed because the changing standard of care landscape, making this trial not impactful anymore.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-06-25